Is it the weight loss thats leading to favorable outcomes
The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection
Medicare enrollees are more likely to think the Trump administration policies will help people like them
The FAERS database also revealed 41 reported cases for semaglutide with an ROR of 11.36 (95% CI, 8.33 to 15.49) and a PRR of 11.36 (95% CI, 8.32 to 15.47), suggesting a potential causal relationship between semaglutide and NAION [98]
These foods dont just taste good
6.2 Modulation of gut microbiota Recent research suggests that GLP-1 receptor agonists significantly affect the composition of gut microbiota, revealing a new mechanism that contributes to metabolic advantages (Liang et al